palivizumab /kg is one of 2 biologic programs targeting Respiratory Syncytial Virus (RSV). It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
4 competitors in Respiratory Syncytial Virus (RSV)
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details